Trial Profile
Phase 1 Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Mogamulizumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin; Ono Pharmaceutical
- 27 Aug 2019 Results published in the Clinical Cancer Research
- 09 Jun 2019 Status changed from active, no longer recruiting to completed.
- 22 Jan 2018 Planned End Date changed to 1 Oct 2019.